Phosphate binder product use, by DOPPS country and cross-section

  Ca-based only Sevelamer only Ca + sev. only Other
N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd %
DOPPS Country DOPPS Cross-section 128 57.4% 39 16.6% 25 10.4% 35 15.6%
AusNZ D4(2010)
D4(2011) 143 54.5% 54 18.0% 34 11.8% 40 15.7%
Belgium D4(2010) 166 54.4% 47 13.2% 89 27.7% 18 4.8%
D4(2011) 163 54.3% 49 14.9% 93 27.5% 13 3.3%
Canada D4(2010) 172 67.7% 41 12.4% 41 12.8% 18 7.1%
D4(2011) 235 68.0% 55 13.6% 63 13.8% 12 4.6%
France D4(2010) 84 33.1% 73 28.9% 59 26.3% 32 11.6%
D4(2011) 93 27.7% 104 33.0% 87 27.6% 39 11.7%
Germany D4(2010) 200 47.6% 83 19.3% 61 15.8% 78 17.3%
D4(2011) 180 41.3% 90 20.4% 59 14.7% 111 23.6%
Italy D4(2010) 90 22.7% 190 42.8% 63 15.0% 70 19.4%
D4(2011) 77 17.9% 239 52.5% 59 12.5% 70 17.0%
Japan D4(2010) 669 58.1% 159 13.4% 256 19.8% 100 8.7%
D4(2011) 654 60.6% 137 10.6% 207 16.9% 126 11.9%
Spain D4(2010) 110 29.5% 114 33.4% 64 17.1% 72 19.9%
D4(2011) 77 21.7% 135 39.7% 42 12.4% 98 26.2%
Sweden D4(2010) 92 26.2% 104 32.1% 70 20.7% 69 21.1%
D4(2011) 97 24.7% 149 37.9% 88 22.2% 68 15.1%
UK D4(2010) 146 60.3% 64 21.7% 10 3.0% 40 15.1%
D4(2011) 151 48.8% 84 25.9% 14 3.5% 62 21.9%
US D4(2010) 1,033 37.1% 1,111 44.7% 329 11.8% 149 6.3%
D4(2011) 1,095 39.0% 1,324 44.2% 386 12.0% 129 4.8%

Medications reported as prescribed (not necessarily taken) in previous week (D2-D3) or end of study month (D4), among treated patients

Please see additional methodological information in the Data Sources and Methods section.